688606 奥泰生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.4955.6247.8454.51831.853
总资产报酬率 ROA (%)0.4645.2257.2874.09927.230
投入资产回报率 ROIC (%)0.4885.5287.6824.36329.997

边际利润分析
销售毛利率 (%)52.91650.94855.71848.78259.933
营业利润率 (%)11.07827.81439.87128.03541.133
息税前利润/营业总收入 (%)18.75526.59035.80618.40538.675
净利润/营业总收入 (%)9.79224.30834.95523.88834.984

收益指标分析
经营活动净收益/利润总额(%)79.00577.14584.73882.361118.590
价值变动净收益/利润总额(%)29.15716.30213.73120.9200.644
营业外收支净额/利润总额(%)0.534-0.2520.631-7.163-0.896

偿债能力分析
流动比率 (X)12.3589.8799.91111.5318.202
速动比率 (X)11.5099.2639.37510.8437.823
资产负债率 (%)5.5196.9797.2296.91211.165
带息债务/全部投入资本 (%)1.1361.3171.7752.0494.131
股东权益/带息债务 (%)8,680.1267,474.4245,527.3914,768.3722,313.053
股东权益/负债合计 (%)1,712.0951,332.9541,283.4251,345.256794.785
利息保障倍数 (X)2.462-23.045-8.290-2.373-18.477

营运能力分析
应收账款周转天数 (天)71.48756.34046.77657.13018.425
存货周转天数 (天)176.913136.597163.664178.00476.563